Meeting The Needs of Patients, Not LDL-C Goals: The Role Of PCSK9 Inhibitors

New Orleans, LA US

Monday, March 25, 2019
Ernest N. Morial Convention Center | Room 294
Registration/Dinner: 5:45 – 6:15 pm | Program: 6:15 – 8:15 pm

This course is a live CME-certified Ancillary Symposium presented at ENDO 2019, held in New Orleans, LA. This educational activity is supported by an independent medical educational grant from Amgen, Inc. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).








Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners, and other healthcare professionals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Summarize the biology and genetic underpinnings of dyslipidemia as related to the LDL receptor.
  • Discuss and identify lipid lowering therapies beyond traditional therapeutics like statins.
  • Recognize the benefit of including PCSK9 inhibitors in the treatment of patients with ASCVD or FH.
  • Assess the clinical trial evidence for the efficacy and safety of PCSK9 inhibitors in patients with statin intolerance.
  • Review the cardiovascular risk reduction provided by PCSK9 inhibitors in combination with statin therapy.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Ernest N. Morial Convention Center, room 294
900 convention center
New Orleans, LA 70130
United States

Program Chair

Sergio Fazio, MD
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR


Savitha Subramanian, MD
University of Washington
Seattle, WA

Eliot Brinton, MD
President, Atherometabolism Institute
Utah Lipid Center
Salt Lake City, UT



The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Sergio Fazio, MD: Ad Hoc consultant, Amgen, Amarin, Akcea, Experion, Astra Zeneca, Novartis
Savitha Subramanian, MD: Advisory Board Member, Sanofi
Eliot Brinton, MD: consultant/advisor, Akcea, Amarin, Amgen, Balchem, Esperion, Kowa, Merck, PTS Diagnostics, Regeneron, Sanofi-Aventis;  speaker, Amarin, Akcea, Amgen, Boehringer-Ingelheim, Kowa, Merck, NovoNordisk, Regeneron, Sanofi-Aventis

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships: 
Neda Rasouli, MD: Research Support, Novo Nordisk, Boehringer Ingelheim, Rhythm Pharmaceuticals, Elira Therapeutics; Consultant, Intarcia

The following SPC members reported relevant financial relationships:
Andrew Ahmann, MD: Research Support, Dexcom, Medtronic; Consultant, Dexcom, Eli Lilly & Company, Horizon CME, MannKind, Novo Nordisk, Sanofi; Speaker, Horizon CME; Principle Investigator, National Institute of Health, T1D Exchange, Trial Net
Giuseppe Barbesino, MD: Advisory Boards, Horizon Pharmaceuticals, Ipsen Pharmaceuticals; Spouse, employee of Genzyme
Joan Han, MD:Research Support, Rhythm Pharmaceuticals; Principle Investigator, Insys Therapeutics, Rhythm Pharmaceuticals
Steven T. Harris, MD:Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health
Jonathan Purnell, MD: Advisor, Novo Nordisk
Amy Rothberg, MD:Spouse, consultant of Merck
Susmeeta Sharma, MD: Speaker, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Deborah Sellmeyer, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Click "Start" to complete the meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™ and 2.0 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions about content or obtaining CME credit, please contact the Endocrine Society at



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Review your Diplomate ABIM ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation